Brainstorm cell therapeutics announces first quarter 2023 financial results and provides corporate update

Biologics license application for nurown® for the treatment of als to be subject of an upcoming fda advisory committee meeting conference call and webcast at 8:00 a.m. eastern time today new york , may 15, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the quarter ended march 31, 2023 and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking